in ASXL1 mutated colorectal cancer cell lines, will be presented on Monday, June 2, 2025, 1:30 PM-4:30 PM CDT. Announced Positive Outcome of Interim Analysis for Phase 3 REGAL Trial of GPS in AML ...

Schmidt College of Medicine have identified a never-before-seen mechanism that enables the human ... inside cells -- unlike regular RNA molecules that are shaped like a straight line.

reverses multiple hallmarks of cellular decline across several human cell lines. The findings include improved mitochondrial activity, reduced oxidative stress, restored calcium balance ...

For AML consolidation in older patients ... The study was conducted in accordance with the Declaration of Helsinki and approved by the Alfred Health Human Research Ethics Committee (ANZ Clinical Trial ...

Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Lead-in completed ... activity in multiply relapsed FLT3-ITD and D835 AML. This ...

The promise of mesenchymal stem cells (MSCs) to heal heart disease could be around the corner thanks to a new delivery method tested by regenerative medicine company Cynata Therapeutics Ltd. Cynata’s ...